INV4
3月前
OneMedNet Moves Ahead With Commercial Rollout of Palantir-Powered Real-World Data Platform
Feb 27, 2026
OneMedNet Corporation (NASDAQ:ONMD) said it is advancing the commercial rollout of its real-world data (RWD) platform built on Palantir Foundry, as the company shifts from customer evaluations toward paid subscriptions following initial demonstrations late last year.
The healthcare data company said the latest phase of the launch follows a November 10, 2025 showcase at major industry conferences, where it presented live data feeds, subscription-based access, and AI-driven search capabilities. Since then, OneMedNet has been converting pilot users and evaluations into commercial agreements, with early adoption highlighting improvements in performance, speed, and analytical capabilities for healthcare and life sciences customers.
According to the company, the launch is helping accelerate subscription growth, including multi-year contracts expected to contribute millions of dollars in recurring revenue. Adoption is expanding among pharmaceutical companies, research organizations, and AI-focused healthcare innovators seeking access to regulatory-grade real-world evidence.
The platform operates through OneMedNet’s iRWD™ network, which now connects more than 2,130 healthcare sites. As the network expands and incorporates additional multimodal datasets, the company said the value of subscriptions increases through broader data diversity, deeper historical coverage, and faster access to insights.
Feedback gathered from customer evaluations conducted since fall 2025 highlighted several strengths, including deeper analytics across integrated clinical and longitudinal datasets, faster cohort identification and feasibility analysis, simplified workflows, and quicker onboarding of new data partners.
For investors, the company said the commercial rollout supports its transition toward a high-margin recurring revenue model. Management noted that conversions from trial evaluations to multi-year subscription agreements are already underway and are expected to generate predictable revenue growth and increased annual recurring revenue as adoption widens.
For customers, the platform is designed to provide near real-time access to multimodal healthcare data, AI-powered search tools capable of identifying complex clinical insights, and accelerated research workflows that reduce the time required to build study cohorts from weeks to minutes. The system is also intended to support real-world evidence study design, regulatory submissions, and clinical research development.
OneMedNet said each dataset integrated into the iRWD platform remains continuously connected to its original source, enabling live updates rather than static data transfers. The company said subscriptions provide longitudinal datasets covering more than 20 years of historical information while continuing to update data for at least three years forward, supporting ongoing analytics, AI model development, and evidence generation.
“OneMedNet’s platform is redefining how organizations access and operationalize real-world data through the continued expansion of our products and solutions,” said Aaron Green, CEO & President. “Customer feedback has reinforced the platform’s performance, speed, and depth of discovery. We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation.”
About OneMedNet Corporation
OneMedNet develops data infrastructure designed to unlock and standardize real-world healthcare data through its iRWD™ platform, which aggregates de-identified medical imaging and electronic health records from a global network of healthcare providers. The company’s datasets support pharmaceutical development, medical device innovation, and artificial intelligence research across therapeutic areas including oncology, cardiology, and rare diseases.
Beyond healthcare applications, OneMedNet also applies proprietary AI technology to anonymize sensitive data for industries such as finance, retail, and telecommunications, enabling secure data sharing, system testing, and risk reduction while protecting personal information.
https://investorshub.advfn.com/stock-market/NASDAQ/onemednet-ONMD/stock-news/97939699/onemednet-moves-ahead-with-commercial-rollout-of-p
$ONMD 🗞️
iHub News
3月前
OneMedNet Moves Ahead With Commercial Rollout of Palantir-Powered Real-World Data PlatformFebruary 27, 2026 10:07 AM
IH Market News
OneMedNet Corporation (NASDAQ:ONMD) said it is advancing the commercial rollout of its real-world data (RWD) platform built on Palantir Foundry, as the company shifts from customer evaluations toward paid subscriptions following initial demonstrations late last year.The healthcare data company said the latest phase of the launch follows a November 10, 2025 showcase at major industry conferences, where it presented live data feeds, subscription-based access, and AI-driven search capabilities. Since then, OneMedNet has been converting pilot users and evaluations into commercial agreements, with early adoption highlighting improvements in performance, speed, and analytical capabilities for healthcare and life sciences customers.According to the company, the launch is helping accelerate subscription growth, including multi-year contracts expected to contribute millions of dollars in recurring revenue. Adoption is expanding among pharmaceutical companies, research organizations, and AI-focused healthcare innovators seeking access to regulatory-grade real-world evidence.The platform operates through OneMedNet’s iRWD network, which now connects more than 2,130 healthcare sites. As the network expands and incorporates additional multimodal datasets, the company said the value of subscriptions increases through broader data diversity, deeper historical coverage, and faster access to insights.Feedback gathered from customer evaluations conducted since fall 2025 highlighted several strengths, including deeper analytics across integrated clinical and longitudinal datasets, faster cohort identification and feasibility analysis, simplified workflows, and quicker onboarding of new data partners.For investors, the company said the commercial rollout supports its transition toward a high-margin recurring revenue model. Management noted that conversions from trial evaluations to multi-year subscription agreements are already underway and are expected to generate predictable revenue growth and increased annual recurring revenue as adoption widens.For customers, the platform is designed to provide near real-time access to multimodal healthcare data, AI-powered search tools capable of identifying complex clinical insights, and accelerated research workflows that reduce the time required to build study cohorts from weeks to minutes. The system is also intended to support real-world evidence study design, regulatory submissions, and clinical research development.OneMedNet said each dataset integrated into the iRWD platform remains continuously connected to its original source, enabling live updates rather than static data transfers. The company said subscriptions provide longitudinal datasets covering more than 20 years of historical information while continuing to update data for at least three years forward, supporting ongoing analytics, AI model development, and evidence generation.“OneMedNet’s platform is redefining how organizations access and operationalize real-world data through the continued expansion of our products and solutions,” said Aaron Green, CEO & President. “Customer feedback has reinforced the platform’s performance, speed, and depth of discovery. We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation.”About OneMedNet CorporationOneMedNet develops data infrastructure designed to unlock and standardize real-world healthcare data through its iRWD platform, which aggregates de-identified medical imaging and electronic health records from a global network of healthcare providers. The company’s datasets support pharmaceutical development, medical device innovation, and artificial intelligence research across therapeutic areas including oncology, cardiology, and rare diseases.Beyond healthcare applications, OneMedNet also applies proprietary AI technology to anonymize sensitive data for industries such as finance, retail, and telecommunications, enabling secure data sharing, system testing, and risk reduction while protecting personal information.Onemednet Corp stock price
Original: OneMedNet Moves Ahead With Commercial Rollout of Palantir-Powered Real-World Data Platform
US Market News
4月前
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B MarketJanuary 27, 2026 3:14 PM
PR Newswire (Canada)
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. This high-stakes convergence positions VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), RadNet (NASDAQ: RDNT), Nanox Imaging (NASDAQ: NNOX), and OneMedNet (NASDAQ: ONMD) as the essential engineering nodes where software-defined 3D modeling finally solves radiologist shortages.
Leading programs at institutions like the Mayo Clinic are proving that subscription-based imaging is the ultimate "cheat code" for patient care, turning diagnostic accuracy into measurable ROI through Device-as-a-Service frameworks[5]. By using cloud-enabled solutions to manage complex heart risks, these companies are building high-margin, recurring revenue streams that align perfectly with the new world of value-based care. This isn't just a tech upgrade; it's a total reimagining of how the world tracks heart health for life.Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation.The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation."We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets.The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation.Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth.The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointIn other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) announced plans to release its Beam Steering API in first half 2026, marking the first time third-party developers will access digital 3D beam steering capabilities for AI-enabled ultrasound applications. The API leverages the company's proprietary semiconductor chip technology featuring approximately 9,000 elements that enable software-defined beam steering with off-axis tilt up to 20 degrees without mechanical motion."As the first to offer digital beam steering access to developers, Butterfly Network is changing the game for imaging AI, empowering more advanced tools that simplify image acquisition," said Steve Cashman, Chief Business Officer of Butterfly Network. "As our platform evolves, Butterfly partners gain access to more of our core imaging capabilities, allowing them to build richer, more sophisticated applications."The planned SDK access will support advanced imaging workflows across multiple presets including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Butterfly Network continues expanding its Butterfly Garden and Ultrasound-on-Chip co-development programs, with availability and technical details dependent on ongoing development, regulatory considerations, and partner agreements to democratize ultrasound technology across clinical settings.RadNet (NASDAQ: RDNT) has acquired Radiology Regional, a division of LucidHealth serving Southwest Florida, expanding RadNet's footprint to 13 locations across Naples, Cape Coral, Fort Myers, Port Charlotte and Sarasota. The acquisition adds approximately 400 employees and 44 contracted radiologists to RadNet's operations, with the transaction projected to contribute approximately $100 million in revenue during 2026."RadNet is proud to enter a dynamic region of Florida and build on Radiology Regional's well-trusted history," said Steve Forthuber, President and CEO of Eastern Operations for RadNet. "Through our clinical excellence, operations expertise and AI-powered digital health solutions, RadNet intends to bring accessible and affordable leading-edge patient care, population health screening programs and a focus on early detection of disease to the communities of Southwest Florida."The 13 acquired centers provide comprehensive multi-modality imaging including MRI, CT, PET/CT, mammography, ultrasound and X-ray services built over Radiology Regional's half-century history. RadNet plans to deploy its DeepHealth AI-powered innovations across the acquired facilities to increase clinical accuracy, streamline imaging processes and improve patient experience in the rapidly growing Southwest Florida market.Nanox Imaging (NASDAQ: NNOX) has expanded operations across Serbia, Montenegro, and Bosnia and Herzegovina through a strategic collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor. The engagement brings the Nanox.ARC multi-source digital tomosynthesis system to healthcare providers throughout the Western Balkans region."We are building momentum in Europe through this strategic collaboration with Adriamed, whose expertise and regional reach will support our commercial expansion in the Western Balkans," said Erez Meltzer, CEO and Acting Chairman of Nanox Imaging. "Our strategy centers on expanding access to cost-effective imaging solutions through established regional partners."Under the agreement, Adriamed becomes Nanox Imaging's exclusive partner for the Nanox.ARC system and related services across the three-country region. The collaboration follows recent distribution agreements in Greece, Romania, Czech Republic and France as Nanox Imaging continues building its European commercial footprint.OneMedNet (NASDAQ: ONMD) has supported FDA 510(k) clearance of mlHealth 360's Scaida BrainCT-ICH, an AI-powered software solution for rapid detection of intracranial hemorrhage from head CT scans. OneMedNet's regulatory-grade Real-World Data spanning longitudinal electronic medical records, diagnostic imaging, and clinical reports played a critical role in supporting model development, validation, and regulatory submission for the software that analyzes head CT images in approximately 5.97 seconds."We are proud to collaborate with our premier partner mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI," said Aaron Green, CEO and President of OneMedNet. "Seeing OneMedNet's regulatory-grade Real-World Data—enriched with medical imaging and EMR context—contribute directly to an FDA-cleared solution reinforces the value of high-quality data in accelerating meaningful innovation."This milestone validates OneMedNet's position as a leading Real-World Data provider as life science and AI companies increasingly rely on OneMedNet to support FDA submissions. The depth, diversity, and quality of OneMedNet's curated imaging and clinical datasets enabled mlHealth 360 to access fit-for-purpose data while maintaining data integrity and regulatory compliance.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1. https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market
2. https://www.bloomberg.com/news/articles/2026-01-23/new-potent-cancer-treatments-are-raising-heart-risks-for-survivors
3. https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report
4. https://www.jacc.org/doi/10.1016/j.jaccao.2025.08.001
5. https://link.springer.com/article/10.1186/s40959-016-0014-2 Logo - https://mma.prnewswire.com/media/2838876/5737507/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-medical-imaging-revolution-software-native-tech-disrupts-45b-market-302671377.html
Original: AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
luckydude777
8月前
From Google: https://www.google.com/search?q=who+are+some+of+the+clients+of+onemednet+inc.&oq=who+are+some+of+the+clients+of+onemednet+inc.&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRigATIHCAUQIRifBTIHCAYQIRiPAjIHCAcQIRiPAtIBCjExNjM0ajFqMTWoAgiwAgHxBcvQqwwMp-FK8QXL0KsMDKfhSg&sourceid=chrome&ie=UTF-8
OneMedNet does not publicly disclose a complete list of its clients, but it has revealed several key partners and customer segments. The company provides regulatory-grade real-world data (RWD) from its network of healthcare providers to life sciences companies, medical device makers, and AI developers.
Key clients and partners
Palantir Technologies: In October 2025, OneMedNet announced a major partnership to integrate Palantir's Artificial Intelligence Platform into its own system. The goal is to accelerate the development of healthcare AI solutions for their mutual customers.
Medcase: OneMedNet has partnered with Medcase to expand into the healthcare data annotation market. Medcase has a network of over 15,000 clinicians, which enhances OneMedNet's ability to provide high-quality, annotated RWD.
Protege AI: As of April 2025, OneMedNet data is available to the AI developer community through a partnership with Protege AI. This allows AI models to be trained using a wider range of clinical data, including medical imaging and other diagnostic data.
Computational biotechnology organization: In June 2024, OneMedNet announced it had secured a significant new client, a computational biotechnology organization, through the Amazon Web Services (AWS) Marketplace. The client remains undisclosed.
Top medical device leaders:
In August 2025, the company announced an evergreen agreement with an unnamed "Top Medical Device Leader" for its iRWD™ platform.
In May 2024, OneMedNet signed an agreement with a "Global Top-10 Medical Technology Company" that impacts over 150 million patients annually.
Client categories
Beyond the named partners, OneMedNet serves the following types of customers:
Life sciences organizations: Companies in this sector use OneMedNet's data for clinical trials, research, and drug development.
Medical device companies: These clients leverage the platform for product development and post-market surveillance.
Healthcare AI developers: This includes AI visionaries and startups that use the clinical data to train their models.
Data contributors
The data that OneMedNet's clients access is sourced from a network of over 1,750 healthcare provider sites, including a large academic research medical center and cancer center.
georgie18
8月前
ONMD...$2.26...🥳...All out in this range from my .60/70 and 80s...
georgie18
Member Level
Re: georgie18 post# 699939
Monday, October 06, 2025 7:20:29 AM
Post#
701142
of 701212
ONMD...$1.47...🥳...Off my .60 Alert... https://www.businesswire.com/news/home/20251006304673/en/OneMedNet-Selects-Palantir-to-Advance-Healthcare-AI-and-Data-Analytics
georgie18
Member Level
Re: georgie18 post# 397750
Wednesday, September 24, 2025 7:43:36 PM
Post#
398634
of 399081
ONMD...$1.03...🥳...Off my .60 range Alert...Took 1/2 off the table...
georgie18
Member Level
Re: georgie18 post# 696277
Thursday, September 04, 2025 9:29:00 AM
Post#
696717
of 699938
ONMD...8937...🥳
georgie18
Member Level
Re: georgie18 post# 397511
Friday, August 29, 2025 9:59:14 AM
Post#
397593
of 397749
ONMD...8418...🥳...Looking for a Triple Top Breakout here...
georgie18
Member Level
Re: georgie18 post# 695935
Wednesday, August 27, 2025 1:23:57 PM
Post#
695952
of 696276
ONMD...7967...🥳...Beatiful Bullish Engulfing Candle...
georgie18
Member Level
Re: georgie18 post# 397263
Wednesday, August 27, 2025 11:40:35 AM
Post#
397487
of 397509
ONMD...758...🥳
georgie18
Member Level
Re: georgie18 post# 694807
Monday, August 25, 2025 8:31:38 AM
Post#
695498
of 695934
ONMD...90...Hit $1.14 Thie Morning...off my .60 range alert...
georgie18
Member Level
Re: georgie18 post# 397009
Monday, August 18, 2025 1:55:59 PM
Post#
397011
of 397262
ONMD...91s clearing here...🥳...Another Runner...Off my .60 range Alerts...
georgie18
Member Level
Re: georgie18 post# 694803
Monday, August 18, 2025 1:50:44 PM
Post#
694804
of 694804
ONMD...84s clearing on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 397006
Monday, August 18, 2025 1:45:03 PM
Post#
397008
of 397008
ONMD...77s clearing here on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 694735
Monday, August 18, 2025 1:41:00 PM
Post#
694800
of 694802
ONMD...7142...🥳...Hod...60 Range dip buys looking better here...
georgie18
Member Level
Re: georgie18 post# 396961
Monday, August 18, 2025 9:04:05 AM
Post#
396971
of 397005
ONMD...6778...🥳...Nice Pop off this mornings .6079...
georgie18
Member Level
Re: georgie18 post# 694562
Monday, August 18, 2025 7:28:31 AM
Post#
694722
of 694734
ONMD...6079...Zero Borrow...Added this range...🥳
georgie18
Member Level
Re: None
Friday, August 15, 2025 8:30:12 AM
Post#
396904
of 396959
ONMD...68...🥳...Took a starter on the .62 Dip...Ran to $1.20 in the A/H yesterday on 300 Million Volume...Will add up or down...
georgie18
Member Level
Re: None
Thursday, August 14, 2025 3:47:12 PM
Post#
694501
of 694560
ONMD...88...🥳...Waiting for a dip....https://finviz.com/news/140491/onemednet-reports-80-reduction-in-debt-enabling-focus-on-growth
georgie18
8月前
ONMD...$1.47...🥳...Off my .60 Alert... https://www.businesswire.com/news/home/20251006304673/en/OneMedNet-Selects-Palantir-to-Advance-Healthcare-AI-and-Data-Analytics
georgie18
Member Level
Re: georgie18 post# 397750
Wednesday, September 24, 2025 7:43:36 PM
Post#
398634
of 399081
ONMD...$1.03...🥳...Off my .60 range Alert...Took 1/2 off the table...
georgie18
Member Level
Re: georgie18 post# 696277
Thursday, September 04, 2025 9:29:00 AM
Post#
696717
of 699938
ONMD...8937...🥳
georgie18
Member Level
Re: georgie18 post# 397511
Friday, August 29, 2025 9:59:14 AM
Post#
397593
of 397749
ONMD...8418...🥳...Looking for a Triple Top Breakout here...
georgie18
Member Level
Re: georgie18 post# 695935
Wednesday, August 27, 2025 1:23:57 PM
Post#
695952
of 696276
ONMD...7967...🥳...Beatiful Bullish Engulfing Candle...
georgie18
Member Level
Re: georgie18 post# 397263
Wednesday, August 27, 2025 11:40:35 AM
Post#
397487
of 397509
ONMD...758...🥳
georgie18
Member Level
Re: georgie18 post# 694807
Monday, August 25, 2025 8:31:38 AM
Post#
695498
of 695934
ONMD...90...Hit $1.14 Thie Morning...off my .60 range alert...
georgie18
Member Level
Re: georgie18 post# 397009
Monday, August 18, 2025 1:55:59 PM
Post#
397011
of 397262
ONMD...91s clearing here...🥳...Another Runner...Off my .60 range Alerts...
georgie18
Member Level
Re: georgie18 post# 694803
Monday, August 18, 2025 1:50:44 PM
Post#
694804
of 694804
ONMD...84s clearing on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 397006
Monday, August 18, 2025 1:45:03 PM
Post#
397008
of 397008
ONMD...77s clearing here on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 694735
Monday, August 18, 2025 1:41:00 PM
Post#
694800
of 694802
ONMD...7142...🥳...Hod...60 Range dip buys looking better here...
georgie18
Member Level
Re: georgie18 post# 396961
Monday, August 18, 2025 9:04:05 AM
Post#
396971
of 397005
ONMD...6778...🥳...Nice Pop off this mornings .6079...
georgie18
Member Level
Re: georgie18 post# 694562
Monday, August 18, 2025 7:28:31 AM
Post#
694722
of 694734
ONMD...6079...Zero Borrow...Added this range...🥳
georgie18
Member Level
Re: None
Friday, August 15, 2025 8:30:12 AM
Post#
396904
of 396959
ONMD...68...🥳...Took a starter on the .62 Dip...Ran to $1.20 in the A/H yesterday on 300 Million Volume...Will add up or down...
georgie18
Member Level
Re: None
Thursday, August 14, 2025 3:47:12 PM
Post#
694501
of 694560
ONMD...88...🥳...Waiting for a dip....https://finviz.com/news/140491/onemednet-reports-80-reduction-in-debt-enabling-focus-on-growth
georgie18
8月前
ONMD...$1.03...🥳...Off my .60 range Alert...Took 1/2 off the table...
georgie18
Member Level
Re: georgie18 post# 696277
Thursday, September 04, 2025 9:29:00 AM
Post#
696717
of 699938
ONMD...8937...🥳
georgie18
Member Level
Re: georgie18 post# 397511
Friday, August 29, 2025 9:59:14 AM
Post#
397593
of 397749
ONMD...8418...🥳...Looking for a Triple Top Breakout here...
georgie18
Member Level
Re: georgie18 post# 695935
Wednesday, August 27, 2025 1:23:57 PM
Post#
695952
of 696276
ONMD...7967...🥳...Beatiful Bullish Engulfing Candle...
georgie18
Member Level
Re: georgie18 post# 397263
Wednesday, August 27, 2025 11:40:35 AM
Post#
397487
of 397509
ONMD...758...🥳
georgie18
Member Level
Re: georgie18 post# 694807
Monday, August 25, 2025 8:31:38 AM
Post#
695498
of 695934
ONMD...90...Hit $1.14 Thie Morning...off my .60 range alert...
georgie18
Member Level
Re: georgie18 post# 397009
Monday, August 18, 2025 1:55:59 PM
Post#
397011
of 397262
ONMD...91s clearing here...🥳...Another Runner...Off my .60 range Alerts...
georgie18
Member Level
Re: georgie18 post# 694803
Monday, August 18, 2025 1:50:44 PM
Post#
694804
of 694804
ONMD...84s clearing on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 397006
Monday, August 18, 2025 1:45:03 PM
Post#
397008
of 397008
ONMD...77s clearing here on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 694735
Monday, August 18, 2025 1:41:00 PM
Post#
694800
of 694802
ONMD...7142...🥳...Hod...60 Range dip buys looking better here...
georgie18
Member Level
Re: georgie18 post# 396961
Monday, August 18, 2025 9:04:05 AM
Post#
396971
of 397005
ONMD...6778...🥳...Nice Pop off this mornings .6079...
georgie18
Member Level
Re: georgie18 post# 694562
Monday, August 18, 2025 7:28:31 AM
Post#
694722
of 694734
ONMD...6079...Zero Borrow...Added this range...🥳
georgie18
Member Level
Re: None
Friday, August 15, 2025 8:30:12 AM
Post#
396904
of 396959
ONMD...68...🥳...Took a starter on the .62 Dip...Ran to $1.20 in the A/H yesterday on 300 Million Volume...Will add up or down...
georgie18
Member Level
Re: None
Thursday, August 14, 2025 3:47:12 PM
Post#
694501
of 694560
ONMD...88...🥳...Waiting for a dip....https://finviz.com/news/140491/onemednet-reports-80-reduction-in-debt-enabling-focus-on-growth
georgie18
9月前
ONMD...8937...🥳
georgie18
Member Level
Re: georgie18 post# 397511
Friday, August 29, 2025 9:59:14 AM
Post#
397593
of 397749
ONMD...8418...🥳...Looking for a Triple Top Breakout here...
georgie18
Member Level
Re: georgie18 post# 695935
Wednesday, August 27, 2025 1:23:57 PM
Post#
695952
of 696276
ONMD...7967...🥳...Beatiful Bullish Engulfing Candle...
georgie18
Member Level
Re: georgie18 post# 397263
Wednesday, August 27, 2025 11:40:35 AM
Post#
397487
of 397509
ONMD...758...🥳
georgie18
Member Level
Re: georgie18 post# 694807
Monday, August 25, 2025 8:31:38 AM
Post#
695498
of 695934
ONMD...90...Hit $1.14 Thie Morning...off my .60 range alert...
georgie18
Member Level
Re: georgie18 post# 397009
Monday, August 18, 2025 1:55:59 PM
Post#
397011
of 397262
ONMD...91s clearing here...🥳...Another Runner...Off my .60 range Alerts...
georgie18
Member Level
Re: georgie18 post# 694803
Monday, August 18, 2025 1:50:44 PM
Post#
694804
of 694804
ONMD...84s clearing on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 397006
Monday, August 18, 2025 1:45:03 PM
Post#
397008
of 397008
ONMD...77s clearing here on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 694735
Monday, August 18, 2025 1:41:00 PM
Post#
694800
of 694802
ONMD...7142...🥳...Hod...60 Range dip buys looking better here...
georgie18
Member Level
Re: georgie18 post# 396961
Monday, August 18, 2025 9:04:05 AM
Post#
396971
of 397005
ONMD...6778...🥳...Nice Pop off this mornings .6079...
georgie18
Member Level
Re: georgie18 post# 694562
Monday, August 18, 2025 7:28:31 AM
Post#
694722
of 694734
ONMD...6079...Zero Borrow...Added this range...🥳
georgie18
Member Level
Re: None
Friday, August 15, 2025 8:30:12 AM
Post#
396904
of 396959
ONMD...68...🥳...Took a starter on the .62 Dip...Ran to $1.20 in the A/H yesterday on 300 Million Volume...Will add up or down...
georgie18
Member Level
Re: None
Thursday, August 14, 2025 3:47:12 PM
Post#
694501
of 694560
ONMD...88...🥳...Waiting for a dip....https://finviz.com/news/140491/onemednet-reports-80-reduction-in-debt-enabling-focus-on-growth
georgie18
9月前
ONMD...8418...🥳...Looking for a Triple Top Breakout here...
georgie18
Member Level
Re: georgie18 post# 695935
Wednesday, August 27, 2025 1:23:57 PM
Post#
695952
of 696276
ONMD...7967...🥳...Beatiful Bullish Engulfing Candle...
georgie18
Member Level
Re: georgie18 post# 397263
Wednesday, August 27, 2025 11:40:35 AM
Post#
397487
of 397509
ONMD...758...🥳
georgie18
Member Level
Re: georgie18 post# 694807
Monday, August 25, 2025 8:31:38 AM
Post#
695498
of 695934
ONMD...90...Hit $1.14 Thie Morning...off my .60 range alert...
georgie18
Member Level
Re: georgie18 post# 397009
Monday, August 18, 2025 1:55:59 PM
Post#
397011
of 397262
ONMD...91s clearing here...🥳...Another Runner...Off my .60 range Alerts...
georgie18
Member Level
Re: georgie18 post# 694803
Monday, August 18, 2025 1:50:44 PM
Post#
694804
of 694804
ONMD...84s clearing on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 397006
Monday, August 18, 2025 1:45:03 PM
Post#
397008
of 397008
ONMD...77s clearing here on the Breakout...🥳
georgie18
Member Level
Re: georgie18 post# 694735
Monday, August 18, 2025 1:41:00 PM
Post#
694800
of 694802
ONMD...7142...🥳...Hod...60 Range dip buys looking better here...
georgie18
Member Level
Re: georgie18 post# 396961
Monday, August 18, 2025 9:04:05 AM
Post#
396971
of 397005
ONMD...6778...🥳...Nice Pop off this mornings .6079...
georgie18
Member Level
Re: georgie18 post# 694562
Monday, August 18, 2025 7:28:31 AM
Post#
694722
of 694734
ONMD...6079...Zero Borrow...Added this range...🥳
georgie18
Member Level
Re: None
Friday, August 15, 2025 8:30:12 AM
Post#
396904
of 396959
ONMD...68...🥳...Took a starter on the .62 Dip...Ran to $1.20 in the A/H yesterday on 300 Million Volume...Will add up or down...
georgie18
Member Level
Re: None
Thursday, August 14, 2025 3:47:12 PM
Post#
694501
of 694560
ONMD...88...🥳...Waiting for a dip....https://finviz.com/news/140491/onemednet-reports-80-reduction-in-debt-enabling-focus-on-growth